Extra-intestinal manifestations in inflammatory bowel disease
Abstract
Extraintestinal manifestations (EIMs) in patients with inflammatory bowel diseases (IBD) are immuno-mediated conditions that may occur in up to 50% of IBD patients. Several organ systems may be involved such as joints, skin, liver, and eyes. EIMs may occur before or after the diagnosis of IBD but the pathogenic mechanisms are still poorly defined. Some of them such as peripheral arthritis, erythema nodosum, aphthous stomatitis, episcleritis, and uveitis are associated to IBD activity and are responsive to IBD-therapies while others like pyoderma gangrenosum, axial spondylarthropathy or primary sclerosing cholangitis follow an independent course and require specific treatments. The present review provides an overview on the classification of the main groups of EIMs occurring in IBD patients.
Keywords
Full Text:
PDFReferences
1. Baumgart, D.C., Sandborn, W.J., (2012) Crohn’s disease. Lancet.;380(9853):1590–1605.
2. Ordás, I., Eckmann, L., Talamini, M., Baumgart, D.C., Sandborn, W.J.,(2012) Ulcerative colitis. Lancet.;380(9853):1606-19.
3. Harbord, M., Annese, V., Vavricka, S.R., Allez, M., Barreiro-de Acosta, M., Boberg, K.M., Burisch, J., De Vos, M., De Vries, A.M., Dick, A.D., Juillerat, P., Karlsen, T.H., Koutroubakis, I., Lakatos, P.L., Orchard, T., Papay, P., Raine, T., Reinshagen, M., Thaci, D., Tilg, H., Carbonnel, F.; European Crohn’s and Colitis Organisation.,(2016) The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis.;10(3):239-54.
4. Bernstein, C.N., Benchimol, E.I., Bitton, A., Murthy, S.K., Nguyen, G.C., Lee, K., Cooke-Lauder, J., Kaplan, G.G.,(2019) The Impact of Inflammatory Bowel Disease in Canada 2018: Extra-intestinal Diseases in IBD.J Can Assoc Gastroenterol.;2(Suppl 1):S73-S80.
5. Bernstein, C.N., Wajda, A., Blanchard, J.F., (2005) The clustering of other chronic inflammatory diseases in inflammatory bowel disease: A population-based study. Gastroenterology.;129(3):827–836.
6. Hedin, C.R.H., Vavricka, S.R., Stagg, A.J., Schoepfer, A., Raine, T., Puig, L., Pleyer, U., Navarini, A., van der Meulen-de Jong, A.E., Maul, J., Katsanos, K., Kagramanova, A., Greuter, T., González-Lama, Y., van Gaalen, F., Ellul, P., Burisch, J., Bettenworth, D., Becker, M.D., Bamias, G., Rieder, F., (2019) The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy.J Crohns Colitis.;13(5):541-554.
7. Isene, R., Bernklev, T., Høie, O., Munkholm, P., Tsianos, E., Stockbrügger, R., Odes, S., Palm, Ø., Småstuen, M., Moum, B., EC-IBD Study Group., (2015) Extraintestinal manifestations in Crohn's disease and ulcerative colitis: results from a prospective, population-based European inception cohort. Scand J Gastroenterol.;50(3):300-305.
8.Vavricka, S.R., Brun, L., Ballabeni, P., Pittet, V., Prinz Vavricka, B.M., Zeitz, J., Rogler. G., Schoepfer, A.M.,(2011) Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort.Am J Gastroenterol.;106(1):110-119.
9. Vavricka, S.R., Rogler, G., Gantenbein, C., Spoerri, M., PrinzVavricka, M., Navarini, A.A., French, L.E., Safroneeva, E., Fournier, N., Straumann, A., Froehlich, F., Fried, M., Michetti, P., Seibold, F., Lakatos, P.L., Peyrin-Biroulet, L., SchoepferA.M.,(2015) Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis.;21(8):1794-800.
10. Rankin, G.B., Watts, H.D., Melnyk, C.S, Kelley, M.L. Jr.,(1979) National Cooperative Crohn’s Disease Study: extraintestinal manifestations and perianal complications. Gastroenterology.;77(4): 914–920.
11. Herzog, D., Fournier, N., Buehr, P., Rueger, V., Koller, R., Heyland, K., Nydegger, A., Spalinger, J., Schibli, S., Petit, L.M., Braegger, C.P.; Swiss IBD Cohort Study Group.,(2018) Age at disease onset of inflammatory bowel disease is associated with later extraintestinal manifestations and complications.Eur J Gastroenterol Hepatol.;30(6):598-607.
12. Duricova, D., Sarter, H., Savoye, G., Leroyer, A., Pariente, B., Armengol-Debeir, L, Bouguen,G., Ley, D., Turck, D., Templier, C., Buche, S., Peyrin-Biroulet, L., Gower-Rousseau, C., Fumery, M., Epimad Group.,(2019) Impact of Extra-Intestinal Manifestations at Diagnosis on Disease Outcome in Pediatric- and Elderly-Onset Crohn's Disease: A French Population-Based Study.Inflamm Bowel Dis.;25(2):394-402.
13. Hillan, K.J., Hagler, K.E., MacSween, R.N., Ryan, A.M., Renz, M.E., Chiu, H.H., Ferrier, R.K., Bird, G.L., Dhillon, A.P., Ferrell, L.D., Fong, S.,(1999) Expression of the mucosal vascular addressin,MAdCAM-1, in inflammatory liver disease. Liver.;19(6):509-518.
14. Eksteen, B., Grant, A.J., Miles, A., Curbishley, S.M., Lalor, P.F., Hübscher, S.G., Briskin, M., Salmon, M., Adams, D.H., (2004) Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis.J Exp Med.;200(11):1511-1517.
15. Salmi, M., Andrew, D.P., Butcher, E.C., Jalkanen, S.,(1995) Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms.J Exp Med.;181(1):137-149.
16. Lora, L., Mazzon, E., Martines, D., Fries, W., Muraca, M., Martin, A., d'Odorico, A., Naccarato, R., Citi, S.,(1997) Hepatocyte tight-junctional permeability is increased in rat experimental colitis.Gastroenterology.;113(4):1347-1354.
17. Horai, R., Zárate-Bladés, C.R., Dillenburg-Pilla, P., Chen, J., Kielczewski, J.L., Silver, P.B., Jittayasothorn, Y., Chan, C.C., Yamane, H., Honda, K., Caspi, R.R.,(2015) Microbiota-Dependent Activation of an Autoreactive T Cell Receptor Provokes Autoimmunity in an Immunologically Privileged Site.Immunity.;43(2):343-353.
18. Taurog, J.D., Richardson, J.A., Croft, J.T., Simmons, W.A., Zhou, M., Fernández-Sueiro, J.L., Balish, E., Hammer, R.E.,(1994) The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med.;180(6):2359-2364.
19. Biancone, L., Mandal, A., Yang, H., Dasgupta, T., Paoluzi, A.O., Marcheggiano, A., Paoluzi, P., Pallone, F., Das, K.M.,(1995)Production of immunoglobulin G and G1 antibodies to cytoskeletalprotein by lamina propria cells in ulcerative colitis.Gastroenterology.;109(1):3-12
20. Bhagat, S., Das, K.M.,(1994) A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody.Gastroenterology.;107(1):103-8.
21. Park J.H., Peyrin-Biroulet L., Eisenhut M., Shin J.I.,(2017) IBD immunopathogenesis: A comprehensive review of inflammatory molecules.Autoimmun Rev.;16(4):416-426.
22. Nikolaus, S., Bauditz, J., Gionchetti, P., Witt, C., Lochs, H., Schreiber, S.,(1998)Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation.Gut. 1998;42(4):470-6.
23. Parkes, M., Cortes, A., van Heel, D.A., Brown, M.A., (2013) Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet.;14(9):661-73.
24. Severs, M., van Erp, S.J., van der Valk, M.E., Mangen, M.J., Fidder, H.H., van der Have, M., van Bodegraven, A.A., de Jong, D.J., van der Woude, C.J., Romberg-Camps, M.J., Clemens, C.H., Jansen, J.M., van de Meeberg, P.C., Mahmmod, N., Ponsioen, C.Y., Bolwerk, C., Vermeijden, J.R., Pierik, M.J., Siersema, P.D., Leenders, M., van der Meulen-de Jong, A.E., Dijkstra, G., Oldenburg, B.; Dutch Initiative on Crohn and Colitis.,(2016) Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis.;10(4):455-61.
25. Vavricka, S.R., Brun, L., Ballabeni, P.L., Pittet, V., Prinz Vavricka, B.M., Zeitz, J., Rogler, G., Schoepfer, A.M.,(2011)Frequency and risk factors for extraintestinal manifestations in the Swiss Inflammatory Bowel Disease Cohort. Am J Gastroenterol.;106(1):110–119.
26. Satsangi, J., Grootscholten, C., Holt, H., Jewell, D.P.,(1996) Clinical patterns of familial inflammatory bowel disease. Gut 38(5):738–741.
27. Orchard, T.R., Thiyagaraja, S., Welsh, K.I., Wordsworth, B.P., Hill Gaston, J.S., Jewell, D.P.(2000) et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology.;118(2):274-278.
28. Orchard, T.R., Chua, C.N., Ahmad, T., Cheng, H., Welsh, K.I., Jewell, D.P.,(2005) Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology.;123(3):714–718.
29. Danese, S., Semeraro, S., Papa, A. Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A.,(2005)Extraintestinalmanifestations in inflammatoryboweldisease. World J Gastroenterol.; 11(46):7227–7236.
30. Roussomoustakaki, M., Satsangi, J., Welsh, K., Louis E., Fanning, G., Targan, S., Landers, C., Jewell, D.P.,(1997). Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology.;112(6):1845–1853.
31. Peeters, H., Vander, C., Laukens, D., Coucke, P., Marichal, D., Van Den Berghe, M., Cuvelier, C., Remaut, E., Mielants, H., De Keyser, F, Vos, M.D.,(2004). Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn’s disease. Ann. Rheum. Dis.;63(9):1131–1134.
32. Leclerc‑Jacob, S., Lux, G., Rat, A.C., Laurent, V., Blum, A.,Chary-Valckenaere, I.,Peyrin-Biroulet, L.,Loeuille, D.,(2014) The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: A retrospective study performed on 186 patients. Aliment Pharmacol Ther.;39(9):957‑962.
33. Salvarani, C., Fries, W.,(2009) Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease.World J Gastroenterol.;15(20):2449-2455.
34. Atzeni, F., Defendenti, C., Ditto, M.C., Batticciotto, A., Ventura, D., Antivalle, M., Ardizzone, S., Sarzi-Puttini, P.,(2014) Rheumaticmanifestations in inflammatoryboweldisease.Autoimmun Rev.;13(1):20-3.
35. Orchard, T.R., Wordsworth, B.P., Jewell, D.P.,(1998) Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut.; 42(3):387–391.
36. Ossum, A.M., Palm, Ø., Cvancarova, M., Solberg, I.C., Vatn, M., Moum, B., Høivik, M.L.; IBSEN study group.,(2018) Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study.Scand J Gastroenterol.;53(10-11):1250-1256.
37. Rudwaleit, M., Baeten, D.,(2006) Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol.;20(3):451–71.
38. López de Castro, J.A.,(2007)HLA-B27 and the pathogenesis of spondyloarthropathies.
Immunol Lett.;108(1):27-33.
39. Clegg, D.O., Reda, D.J., Abdellatif, M.,(1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum.;42(11):2325–2329.
40. Peyrin-Biroulet, L., Van Assche, G., Gómez-Ulloa, D., García-Álvarez, L., Lara, N., Black, C.M., Kachroo, S.,(2017) Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. ClinGastroenterol Hepatol.;15(1):25–36.e27.
41. Ostendorf, B., Specker, C., Schneider, M.,(1998) Methotrexate lacks efficacy in the treatment of severe ankylosing spondylitis compared with rheumatoid and psoriatic arthritis. J Clin Rheumatol.;4(3):129–136.
42 Tadbiri, S., Peyrin-Biroulet, L., Serrero, M., Filippi, J., Pariente, B., Roblin, X., Buisson, A., Stefanescu, C., Trang-Poisson, C., Altwegg, R., Marteau, P., Vaysse, T., Bourrier, A., Nancey, S., Laharie, D., Allez, M., Savoye, G., Gilletta, C., Gagniere, C., Vuitton, L., Viennot, S., Aubourg, A., Pelletier, A.L., Bouguen, G., Abitbol, V., Fumery, M., Claudepierre, P., Bouhnik, Y., Amiot, A.; GETAID OBSERV-IBD study group.,(2018) Impact of vedolizumab therapy on extraintestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV-IBD cohort. Aliment Pharmacol Ther.;47(4):485-493.
43. Macaluso, F.S., Orlando, R., Fries, W., Scolaro, M., Magnano, A., Pluchino, D., Cappello, M., Morreale, G.C., Siringo, S., Privitera, A.C., Ferracane, C., Belluardo, N., Alberghina, N., Ventimiglia, M., Rizzuto, G., Renna, S., Cottone, M., Orlando, A.,(2018) The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.Dig Liver Dis.;50(7):675-681.
44. Troncoso, L.L., Biancardi, A.L., de Moraes, H.V. Jr., Zaltman, C.,(2017) Ophthalmic manifestations in patients with inflammatory bowel disease: A review.World J Gastroenterol.;23(32):5836-5848.
45. Lyons, J.L., Rosenbaum, J.T.,(1997) Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol.;115(1):61‑64.
46. Sharma, S.M., Nestel, A.R., Lee, R.W., Dick, A.D.,(2009) Clinical review: Anti‑TNF alpha therapies in uveitis: Perspective on 5 years of clinical experience. OculImmunol Inflamm.;17(6):403‑14.
47. Greuter. T., Navarini, A., Vavricka, S.R.,(2017) Skin Manifestations of Inflammatory Bowel Disease.Clin Rev Allergy Immunol.;53(3):413-427.
48. Timani, S., Mutasim, D.F., (2008) Skin manifestations of inflammatory bowel disease. ClinDermatol.; 26(3):265–273.
49. Cozzani, E., Gasparini, G., Parodi, A.(2014) Pyoderma gangrenosum: a systematic review.
G Ital Dermatol Venereol.;149(5):587-600.
50. Huang, W., McNeely, M.C.,(1979) Neutrophilic tissue reactions. AdvDermatol.; 13:33–64.
51. Sasor, S.E., Soleimani, T., Chu, M.W., Cook, J.A., Nicksic, P.J., Tholpady, S.S.,(2018) Pyoderma gangrenosum demographics, treatments, and outcomes: an analysis of 2,273 cases.J Wound Care.;27(Suppl1):S4-S8.
52. Brooklyn, T., Dunnill, G., Probert, C.,(2006) Diagnosis and treatment of pyoderma gangrenosum. BMJ.;42:8547–8551.
53. Brooklyn, T.N., Dunnill, M.G., Shetty, A., Bowden, J.J., Williams, J.D., Griffiths, C.E., Forbes, A., Greenwood, R., Probert, C.S.,(2006) Infliximab for the treatment of pyoderma gangrenosum: A randomised, double blind, placebo controlled trial. Gut.;55(4):505‑509.
54. Schrumpf E, Boberg KM. Epidemiology of primary sclerosing cholangitis. Best Pract Res ClinGastroenterol2001;15:553‑562.
55. Venkatesh, P.G., Navaneethan, U., Shen, B.,(2011) Hepatobiliary disorders and complications of inflammatory bowel disease. Dig Dis.;12(4):245–256.
56. Broome, U., Bergquist, A.,(2006) Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis.;26(1):31–41.
57. Chapman, R., Fevery, J., Kalloo, A., Nagorney, D.M., Boberg, K.M., Shneider, B, Gores, G.J., American Association for the Study of Liver Diseases.,(2010) Diagnosis and management of primary sclerosing cholangitis. Hepatology.;51(2):660–678.
58. Sinakos, E., Lindor, K.,(2010) Treatment options for primary sclerosing cholangitis. Expert RevGastroenterol Hepatol.;4(4):473‑488.
59. Schrumpf E, Fausa O, Førre O, et al. HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol. 1982;17(2):187-191.
Orchard, T.R., Chua, C.N., Ahmad, T., Cheng, H., Welsh, K.I., Jewell, D.P.,(2002) Uveitis and erythema nodosum in inflammatory bowel disease: clinical features and the role of HLA genes. Gastroenterology.;123(3): 714–718 (2002).
DOI: https://doi.org/10.6092/1828-6550/APMB.108.1.2020.SD1
Refbacks
- There are currently no refbacks.
Copyright (c) 2020 Anna Viola, Francesco Marino, Fabiola Atzeni, Walter Fries
This work is licensed under a Creative Commons Attribution 4.0 International License.